Integra LifeSciences Promotes Interim Regulatory Chief to Permanent Role
Event summary
- Topaz Kirlew appointed as corporate vice president and chief regulatory officer at Integra LifeSciences, effective July 2026.
- Kirlew previously served as interim regulatory leader since joining the company in 2021.
- She brings over 35 years of experience in healthcare and medical technology, including roles at Danaher Corporation and Apyx Medical.
- Kirlew holds a DBA and MBA from Nova Southeastern University's School of Business and Entrepreneurship.
The big picture
Integra LifeSciences' appointment of Topaz Kirlew as chief regulatory officer underscores the growing importance of regulatory compliance in the medical technology sector. With increasing scrutiny from regulators and a complex global landscape, having a seasoned leader like Kirlew at the helm could be pivotal for Integra's strategic positioning. Her extensive experience across various healthcare organizations suggests a focus on streamlining regulatory processes and mitigating risks.
What we're watching
- Regulatory Strategy
- How Kirlew's leadership will shape Integra's global regulatory affairs and compliance initiatives.
- Operational Efficiency
- Whether the permanent appointment stabilizes regulatory processes after her interim tenure.
- Industry Trends
- The pace at which medical technology companies adopt similar leadership structures to navigate complex regulations.